Introduction
Despite an impressive reduction in death rates of several cancers in women over the past decades, including stomach, uterine, colon, rectal, and breast cancers, the death rates for ovarian cancers have remained unchanged [1] . Ovarian cancers are the fifth leading cause of cancer deaths among women [1] , and recent studies have failed to provide an early diagnosis of ovarian cancers by means of screening biomarkers [2 -4] . There are no known carcinogens or risk factors that can be avoided [5, 6] , and clinical treatment of ovarian cancers, mostly found at a late stage, offers limited hope in prognosis [7, 8] .
Meanwhile, all solid tumors growing beyond 1 mm in diameter face a limiting nutrition and oxygen supply and must establish their own blood vessel networks to support their own growth [9] . Angiogenesis, the establishment of new blood vessels [10] , is therefore necessary for ovarian cancers to grow from early to late stages but is virtually quiescent in normal adult tissues [9] .
Antiangiogenesis is one of the most promising strategies in the prevention and treatment of cancers [11] and is reported to be feasible for treating ovarian cancers [12] .
In the search for antiangiogenic compounds for preventing and treating ovarian cancers, we recently screened over 20 bioactive natural compounds: genistein, kaempferol, apigenin, quercetin, tocopherol, tocopherol succinate, luteolin, rutin, naringin, taxifolin, paclitaxel, gallic acid, chaetoglobosin K (ChK), epicatechin, ellagic acid, catechin hydrate, baicalein, baicalin, tangeretin, nobiletin, and cisplatin for their effects on cell viability and on vascular epithelial growth factor (VEGF) secretion. Among the compounds screened, ChK had the strongest inhibition of cell viability and VEGF secretion in ovarian cancer cells. Therefore, in this study, we focused our anticancer research on ChK. The potential of bioactive compounds such as ChK from fungi has not been studied in much detail, although some flavonoids definitely showed effectiveness in antiangiogenesis [10] .
ChK is a bioactive compound isolated from Diplodia macrospora, a fungus responsible for ear rot and stalk rot of corn [13] . Although the structure of ChK was determined in 1980 [14] , this compound remains largely unexplored, and only a few publications on ChK have been reported over the past three decades. These publications of invitro studies indicate that ChK suppresses the malignant phenotype of ras-transformed fibroblasts and induces apoptosis [15, 16] , prevents organochlorine-induced inhibition of gap junctional communication in astrocytes [17, 18] , inhibits Akt kinase phosphorylation and cytokinesis in ras-transformed liver epithelial cells [19] , and plays a dual inhibition role in both Akt and JNK activation in ras-transformed epithelial and human lung carcinoma cells [20] . In this study, we examined the potentials of ChK in angioprevention of ovarian cancers and its underlying mechanisms. We assessed the effects of ChK on inhibiting the viability of, VEGF secretion in, in-vitro and in-vivo angiogenesis of, and human umbilical vein endothelial cell (HUVEC) migration of ovarian cancer cells. We hypothesized that ChK inhibits cancer angiogenesis through downregulation of hypoxia-inducible factor 1a (HIF-1a).
Materials and methods

Cell lines and reagents
ChK was dissolved in dimethyl sulfoxide (DMSO) as a 100 mmol/l stock solution and stored at -801C. The chemical structure of ChK is shown in Fig. 1 . OVCAR-3 and A2780/CP70 ovarian cancer cell lines were obtained from Dr Binghua Jiang from West Virginia University [21] . Cancer cells were maintained in an RPMI-1640 medium (Sigma-Aldrich, St Louis, Missouri, USA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Grand Island, New York, USA). HUVEC cells were purchased from American Type Culture Collection (ATCC, Manassas, Virginia, USA) and maintained in a vascular cell basal medium (ATCC) supplemented with Endothelial Cell Growth Kit-VEGF (ATCC). All cells were cultured in a cell culture incubator with 5% CO 2 at 371C.
Viability assay
OVCAR-3 and A2780/CP70 cells were seeded onto 96-well plates at 10 000 cells/well and incubated overnight before treatment with various concentrations of ChK (0.5, 1.0, 2.0, 4.0, 6.25, 12.5, and 25.0 mmol/l) and DMSO as a control for 24 h. Cell viability (reflecting the number of viable cells at the time period tested compared with the control) was analyzed with a CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, Wisconsin, USA), following the manufacturer's instructions, and normalized to control wells for statistical analysis. The experiments were conducted three times independently.
Enzyme-linked immunosorbent assay
VEGF protein secretion in ovarian cancer cells was evaluated using an enzyme-linked immunosorbent assay kit. A2780/CP70 and OVCAR-3 ovarian cancer cells were seeded at 10 000 cells/well onto 96-well plates and treated with 150 ml of RPMI-1640 medium containing ChK (0, 0.5, 1, and 2 mmol/l) for 24 h; 100 ml of culture supernatant was collected from each well for the VEGF assay, targeting VEGF 165 with a Quantikine Human VEGF Immunoassay Kit (R&D Systems, Minneapolis, Minnesota, USA) as per instructions. Standard curves generated from recombinant VEGF with known concentrations were used to quantify VEGF levels in the culture supernatants. The experiments were conducted three times.
In-vitro angiogenesis assay A2780/CP70 and OVCAR-3 cancer cells were seeded onto six-well plates, incubated overnight, and treated with 2 ml of a serum-free medium containing ChK (0, 1, and 2 mmol/l) for 24 h. The conditioned medium was collected. For the in-vitro angiogenesis assay, growth factorreduced Matrigels (BD Biosciences, San Jose, California, USA) were transferred into 96-well plates at a concentration of 50 ml/well and incubated at 371C for 1 h to gel. HUVEC cells were harvested in PBS, counted, and seeded onto the Matrigel beds at 20 000 cells/90 ml PBS. Thereafter, volumes of 10 ml of the collected conditioned media were added to each well. The system was incubated at 371C for 8 h, and photographed at Â 50 amplification under a microscope. Each picture of 1388 Â 1040 pixels was further divided by gridlines, and nine squares of 316 Â 316 pixels were measured and averaged to obtain the tube length using the NIH ImageJ software (NIH, Bethesda, Maryland, USA) for statistical analysis.
In-vivo angiogenesis assay
All the experiments were performed on chicken embryos before hatching; our lab has been approved for using chicken embryos by the Institutional Animal Care and Use Committee, West Virginia University. Specific pathogen-free fertile chicken eggs (Charles River Laboratories, North Franklin, Connecticut, USA) were incubated at 37.51C and slowly turned by an automatic egg turner (G.Q.F. Manufacturing Company, Savannah, Georgia, USA). At day 7, the eggs were windowed to expose the chorioallantoic membrane (CAM). At day 9, A2780/CP70 cells (1.2 Â 10 6 cells in a 20 ml FBS-free medium) were mixed with 80 ml Matrigel (BD Biosciences), treated with 2 mmol/l (final concentration) ChK or an equal concentration of DMSO freshly prepared in FBS-free medium, and implanted onto the CAM of chicken embryos. After incubating for another 5 days, tumor implants were photographed, and the number of blood vessels was calculated by two investigators blinded to the treatment. Scores from the two investigators were averaged for statistical analysis.
Migration assay
HUVEC cells were seeded onto six-well plates, cultured to 80% confluence, and stained for 30 min with 2 mmol/l calcein AM (BD Biosciences) freshly prepared in PBS. These cell monolayers were scraped with 10-ml pipet tips to generate two perpendicular acellular lines within each well, washed twice with PBS, and treated with ChK (0, 1, and 2 mmol/l) prepared in a vascular cell basal medium supplemented with Endothelial Cell Growth Kit-VEGF for 8 h. At 0 and 8 h, the acellular lines within each well were photographed at Â 50 amplification under a fluorescence microscope (485 nm excitation/520 nm emission) and counted for the total number of cells that migrated to the acellular areas.
Western blotting A2780/CP70 and OVCAR-3 ovarian cancer cells (1.5 Â 10 6 /dish) were seeded onto 60-mm dishes and incubated overnight. Cells were then treated with various concentrations (0, 0.5, 1, and 2 mmol/l) of ChK for 2 h for Akt determination or for 24 h for detection of other proteins. Cells were lysed with M-PER Mammalian Protein Extraction Reagent (Pierce, Rockford, Illinois, USA) supplemented with Halt Protease and Phosphatase Inhibitor (Pierce) as per instructions. Cell lysates were separated by SDS-PAGE gel electrophoresis and immunoblotted with antibodies against phospho-Akt, total Akt (Cell Signaling Technology, Danvers, Massachusetts, USA), HIF-1a (BD Biosciences), phospho-mTOR, mTOR (R&D Systems), PTEN and GAPDH (Santa Cruz Biotechnology, Santa Cruz, California, USA), NF-kB, and c-Myc. Protein bands were visualized using SuperSignal West Pico substrate (Pierce) and X-ray films (Phenix Research, Candler, North Carolina, USA), quantified with the NIH ImageJ software, and normalized to corresponding load-control proteins for statistical analysis. The experiments were conducted three times.
Transient transfection and reporter assay
Ovarian cancer cells (10 000 cells/well) were seeded onto 96-well plates and incubated overnight. For transfection with HIF-1a plasmids (Addgene, Cambridge, Massachusetts, USA), cells were transfected with VEGF luciferase reporter (0.01 mg), b-galactosidase (0.01 mg), and HIF-1a (0, 0.02, 0.04, and 0.08 mg) or SR-a (as vehicle) plasmids using 0.2 ml of jetPRIME reagent (VWR, West Chester, Pennsylvania, USA) for 4 h, followed by a 16-h treatment with or without ChK (0 and 2 mmol/l). The cells were harvested and analyzed for luciferase activity using a ONE-Glo Luciferase Assay System (Promega) and for b-galactosidase activity using a b-Galactosidase Enzyme Assay System (Promega), as previously described [22] . The levels of VEGF reporter were normalized to corresponding b-galactosidase activities. For transfection with mAkt plasmids (Addgene), cells were transfected with VEGF luciferase reporter (0.05 mg) and with mAkt (0, 0.05, 0.1, and 0.2 mg) or SR-a plasmids using 1 ml of lipofectamine2000 reagent (Invitrogen) for 5 h, followed by an 8-h treatment with or without ChK (0 and 2 mmol/l). The cells were harvested and analyzed for luciferase activity and total protein levels using a BCA Protein Assay Kit (Pierce), and the activities of VEGF reporter were normalized to corresponding total protein levels for statistical analysis. The experiments were conducted three times.
Chromatin immunoprecipitation assay A2780/CP70 cells (7.5 Â 10 6 cells/dish) were seeded onto 100-mm dishes and incubated overnight. Cells were then treated with or without ChK (0 and 2 mmol/l) for 24 h. After treatment, the chromatin immunoprecipitation (ChIP) assay was performed using an EZ ChIP kit (Millipore, Temecula, California, USA) as per the manufacturer's instructions. In brief, cross-linked cells were collected, lysed, sonicated, and subjected to immunoprecipitation with the HIF-1a antibody (Millipore). Immunocomplexes were collected using protein A/G agarose beads and eluted. Cross-links were reversed by incubating the samples at 651C. DNA was extracted and purified. The DNA sequences for the primers used to amplify the VEGF promoter were 5 0 -AGACTCCACAGTGCATACG TG-3 0 (forward) and 5 0 -AGTGTGTCCCTCTGACAA TG-3 0 (reverse).
Samples were analyzed by real-time PCR using the Chromo4 real-time detector (Bio-Rad, Hercules, California, USA). The cycle threshold (C t ) values for each sample were normalized to the C t values of the input samples to obtain DC t . The differences between the normalized experimental samples and the control samples were determined to obtain DDC t . The normalized fold difference relative to the control sample was then calculated using 2 ÀDDC t . Three independent experiments were carried out.
Statistical analysis
Data from three independent experiments were combined for statistical analysis and presented as means±SE.
One-way analysis of variance, followed by Dunnett's test or a t-test, was performed, as appropriate, to determine the differences between the groups using the SPSS software (SPSS Inc., Armonk, New York, USA). A P-value of less than 0.05 was considered significant.
Results
ChK reduces the viability of ovarian cancer cells
The effects of ChK on the viability of A2780/CP70 and OVCAR-3 ovarian cancer cells were first evaluated and optimized. We found that, compared with controls (ChK 0 mmol/l), ChK significantly reduced the viability of A2780/CP70 cells at all concentrations (0.5-25.0 mmol/l) studied and also significantly reduced the viability of OVCAR-3 cells at ChK concentrations of 1.0 mmol/l and above ( Fig. 2) . At 25.0 mmol/l, no viable cells were detected. At the same concentration, no significant differences were observed between A2780/CP70 and OVCAR-3 cells. The results showed that ChK is potent in reducing the viability of ovarian cancer cells.
ChK inhibits VEGF secretion in ovarian cancer cells
For the purpose of angioprevention, levels of VEGF, an important growth factor, were examined. We found that ChK significantly reduced VEGF secretion by A2780/ CP70 cells at concentrations of 1.0 and 2.0 mmol/l and by OVCAR-3 cells at 0.5, 1.0, and 2.0 mmol/l ( Fig. 3 ). At the same ChK concentration, no significant differences were observed between A2780/CP70 and OVCAR-3 cells.
ChK inhibits in-vitro angiogenesis induced by ovarian cancer cells
Reduced secretion of VEGF (Fig. 3 ) by ovarian cancer cells treated with ChK is expected to inhibit angiogenesis because of VEGF's pivotal role in angiogenesis [10] ; therefore, we tested in-vitro tube formation by HUVEC cells induced by the culture medium of ovarian cancer cells treated with different concentrations of ChK. We found that the culture media conditioned by both A2780/ CP70 and OVCAR-3 ovarian cancer cells promoted invitro angiogenesis and presented a well-established network of HUVEC cells, and the medium from A2780/ CP70 cells seemed to be more effective in promoting invitro angiogenesis compared with the medium from OVCAR-3 cells (ChK = 0 mmol/l, Fig. 4a ). ChK treatment, however, led to truncated HUVEC networks (ChK = 1 and 2 mmol/l, Fig. 4a ). A significant reduction in tube length was observed at ChK concentrations of 1 and 2 mmol/l for A2780/CP70 cells and at 2 mmol/l for OVCAR-3 cells when compared with corresponding controls (Fig. 4b ).
ChK inhibits in-vivo angiogenesis induced by ovarian cancer cells
To test the hypothesis that effective inhibition of VEGF secretion by ChK treatment can be translated into antiangiogenic effects in vivo, CAM assays using chicken embryos were performed to determine the effect of ChK treatment on ovarian cancer angiogenesis in vivo. As shown in Fig. 5 , ChK treatment at concentrations of 2 mmol/l significantly reduced the generation of new blood vessels that was induced by A2780/CP70 ovarian cancer cells. 
ChK inhibits the migration of HUVEC cells in plastic culture vessels
HUVEC cell migration assays were performed to determine whether ChK affects the migration of HUVEC cells in plastic culture vessels, as this is relevant to ChK's antiangiogenic attributes. We found that after introducing a 'wound' by scraping monolayer HUVEC cells in culture vessels, the 'wound' showed signs of 'healing' 8 h later by means of HUVEC cells migrating into the acellular area (ChK = 0 mmol/l, Fig. 6 ). However, ChK treatment impaired the migratory capabilities of HUVEC cells cultured in plastic vessels, and at a ChK concentration of 2 mmol/l, significantly fewer HUVEC cells migrated into the acellular areas when compared with controls ( Fig. 6 ).
ChK inhibits VEGF secretion by regulating HIF-1 expression and the interaction of HIF-1a with the VEGF promoter
Because of the close regulation of VEGF secretion by the HIF-1a gene, the expression of HIF-1a at the protein level was determined. ChK treatment significantly inhibited HIF-1a protein expression in both A2780/CP70 and OVCAR-3 cells at concentrations of 0.5, 1, and 2 mmol/l ( Fig. 7a and b ).
To prove that HIF-1a expression is not only regulated by ChK treatment but also plays a role in ChK's inhibition on ChK inhibits in-vitro angiogenesis induced by ovarian cancer cells. A2780/CP70 and OVCAR-3 cells were seeded, treated with ChK (0, 1, and 2 mmol/l) for 24 h, and the media were collected. Growth factor-reduced Matrigels were aliquoted and incubated at 371C for 1 h to gel. HUVEC cells were harvested, counted, and seeded onto the gelled Matrigel beds. The collected conditioned cell culture media were then added to each well. The system was incubated at 371C for 8 h. VEGF secretion, A2780/CP70 and OVCAR-3 cells were transfected with the VEGF-promoter reporter, together with HIF-1a plasmids. Although ChK (2 mmol/l) treatment significantly inhibited VEGF transcriptional activation, this inhibition was significantly reversed by forced expression of the HIF-1a protein, and the higher the expression of HIF-1a, the higher the expression of the VEGF reporter ( Fig. 7c and d) .
To examine whether ChK was involved in targeting HIF-1a to the promoter of VEGF, ChIP assays with HIF-1a antibody were performed, followed by real-time PCR using primers for the VEGF promoter. Results showed that the ChK (2 mmol/l) treatment of A2780/CP70 cells significantly inhibited the interaction of HIF-1a with the VEGF promoter and resulted in significantly less VEGF secretion when compared with controls ( Fig. 7e ).
ChK inhibits VEGF secretion through Akt/mTOR signaling
The phosphorylation of Akt was significantly inhibited by ChK treatment at concentrations of 0.5, 1, and 2 mmol/l when compared with controls ( Fig. 8a and b ). After transfecting with the VEGF-promoter reporter and mAkt plasmids, VEGF transcriptional activation was significantly reduced by ChK (2 mmol/l) treatment in both A2780/CP70 and OVCAR-3 cells, whereas the effect was significantly reversed by forced expression of the Akt protein at a concentration of 0.2 mg of the mAkt plasmid ( Fig. 8c  and d) . The phosphorylation of mTOR was significantly inhibited by ChK treatment at a concentration of 2 mmol/l when compared with controls ( Fig. 8e and f) .
We also looked into protein expressions of PTEN, NF-kB, and c-Myc genes in A2780/CP70 and OVCAR-3 cells treated with and without ChK (0, 0.5, 1, and 2 mmol/l). No significant differences were found among the concentrations studied in both A2780/CP70 and OVCAR-3 cells ( Fig. 8g and h) .
Discussion
A transcription factor controls and regulates gene expression by binding to a particular promoter or enhancer. HIF-1a is a key transcription factor that has been reported to regulate over 258 different genes [23] . HIF-1a is an important mediator of angiogenesis and thus holds great promise as a therapeutic target of angiogenesis [21, 24] . This study reported the functional effects of the cytochalasan compound ChK obtained from D. macrospora as a potent regulator of HIF-1a.
It is generally thought that HIF-1a is regulated mainly by low oxygen or hypoxia as its name indicates. However, we found that HIF-1a is highly expressed in normoxic conditions in ovarian cancer cells [21] . Recent evidence indicates that several nonhypoxic factors can also mediate HIF-1a expression, such as natural nonpeptide bioactive compounds, cytokines, and oncogenic factors [21, 24] , suggesting that ChK may be such a factor for regulating HIF-1a under nonhypoxic conditions. HIF-1a inhibition has not been reported for cytochalasan compounds to our knowledge. Therefore, there is a need to explore ChK as a novel inhibitor of angiogenesis in cancer prevention and treatment.
This study indicates that ChK is an effective HIF-1a protein inhibitor and antiangiogenesis agent. In general, the PTEN/PI3K/Akt/mTOR pathway plays an important role in regulating protein synthesis [25, 26] . We found that ChK inhibits Akt phosphorylation in ovarian cancer cells in the PTEN/PI3K/Akt/mTOR pathway. Our finding agrees well with the finding that ChK inhibited Akt phosphorylation in ras-transformed epithelial cells [19] . These results suggest the involvement of the PI3K pathway in the inhibition of VEGF secretion and angiogenesis. We also found that ChK did not affect protein expression of PTEN, NF-kB, and c-Myc genes in our ovarian cancer system.
The mechanism by which ChK inhibits the PI3K/Akt signaling pathway is not yet fully understood; however, it has been shown that ChK inhibited Akt phosphorylation and cytokinesis in ras-transformed epithelial cells [19] . In human lung carcinoma and ras-transformed epithelial cells, ChK inhibits JNK and Akt phosphorylation [20] . The implication of the bioactive cytochalasan compound inhibiting HIF-1a is intriguing as HIF-1a has been shown to be required in VEGF secretion, which is essential for tumor angiogenesis [21] . Through ChIP assays using the HIF-1a antibody, we found that ChK inhibits the interaction of HIF-1a with the VEGF promoter. By transfecting HIF-1a plasmids in luciferase assays, we found that ChK executes its VEGF inhibition by mediating the hypoxiaindependent downregulation of HIF-1a. Through transfection of Akt plasmids, we found that inhibition of HIF-1a by ChK is through inhibition of Akt phosphorylation. We found that ChK significantly inhibited cell viability in both A2780/CP70 and OVCAR-3 ovarian cancer cells. ChK treatment significantly reduced VEGF secretion in the two ovarian cancer cell lines. Consistent with our hypothesis, ChK treatment effectively reduced angiogenesis induced by ovarian cancer cells in vitro and in vivo and suppressed the migration of HUVEC cells cultured in plastic vessels in the HUVEC cell migration assay. ChK was found to inhibit VEGF secretion in ovarian cancer cells through the Akt-HIF-VEGF pathway (Fig. 9 ). The potency exhibited at low ChK concentrations studied may indicate that ChK is an effective antiangiogenesis agent. 
Conclusion
This study revealed an important mechanism of the antiangiogenic activity of ChK and found that ChK inhibits tumor angiogenesis through downregulation of HIF-1a. ChK was found to significantly inhibit cell viability and VEGF protein secretion in two ovarian cancer cells (i.e. A2780/CP70 and OVCAR-3). ChK was also found to effectively reduce angiogenesis in vitro and in vivo and HUVEC cell migration. In addition, ChK was found to inhibit VEGF secretion in ovarian cancer cells through the Akt-HIF-VEGF pathway. This is the first report on angiogenesis inhibition through downregulation of VEGF-binding HIF-1a by the nonpeptide cytochalasan compound ChK in cancer cells. These findings enhance our understanding of its working mechanism and provide strong support for using this compound in animal model studies. 
